HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a $32 price target.
August 12, 2024 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Iovance Biotherapeutics and maintained a $32 price target.
The reiteration of a Buy rating and the maintenance of a $32 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100